Developments with investigational Janus kinase inhibitors for rheumatoid arthritis

References

• Semerano L, Minichiello E, Bessis N, et al. Novel immunotherapeutic avenues for rheumatoid arthritis. Trends Mol Med. 2016;22:214–229.
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25–36.
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–519.
   PubMed Web of Science ®Google Scholar
• Kremer J, Li Z-G, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159:253–261.
   PubMed Web of Science ®Google Scholar
• Van Der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559–570.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451–460.
   PubMed Web of Science ®Google Scholar
• Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377–2386.
   PubMed Web of Science ®Google Scholar
• Cohen S, Radominski SC, Gomez-Reino JJ, et al. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2924–2937.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Lee EB, Kaplan IV, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2016;75:831–841.
   PubMed Web of Science ®Google Scholar
• Semerano L, Thiolat A, Minichiello E, et al. Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs. Expert Opin Investig Drugs. 2014;23:979–999.
   PubMed Web of Science ®Google Scholar
• Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184:5298–5307.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Takeuchi T, Schlichting DE, et al. Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with Disease-Modifying Anti-Rheumatic Drugs (DMARDs): phase 3 trial results [abstract]. Arthritis Rheumatol. 2015;67(Suppl 10):1045.
   Google Scholar
• Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374:1243–1252.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Keystone EC, Van Der Heijde D, et al. Baricitinib versus placebo or adalimumab in patients with active Rheumatoid Arthritis (RA) and an inadequate response to background methotrexate therapy: results of a Phase 3 study [abstract]. Arthritis Rheumatol. 2015;67(Suppl 10):2L.
   Google Scholar
• Genovese MC, Greenwald M, Codding C, et al. A Phase 2b, randomized, double-blind, parallel-group, placebo-controlled, dose-finding, multi-center study to evaluate the safety and efficacy of ASP015K in moderate to severe rheumatoid arthritis subjects not on concomitant methotrexate [abstract]. Arthritis Rheumatol. 2014;66(Suppl 10):2826.
   Google Scholar
• Takeuchi T, Tanaka Y, Iwasaki M, et al. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis. 2016;75:1057–1064.
   PubMed Web of Science ®Google Scholar
• Galien, R., Brys R, Van der Aa A, et al. Absence of effects of filgotinib on erythrocytes, CD8+ and NK cells in rheumatoid arthritis patients brings further evidence for the JAK1 selectivity of filgotinib [abstract]. Arthritis Rheumatol. 2015;67(Suppl10):2781.
   Google Scholar
• Westhovens R, Alten R, Pavlova D, et al. Filgotinib (GLPG0634), an oral JAK1 selective inhibitor is effective in combination with methotrexate in patients with active rheumatoid arthritis: results from a Phase 2B dose ranging study [abstract]. Arthritis Rheumatol. 2015;67(Suppl10):1048.
   Google Scholar
• Kavanaugh A, Ponce L, Cseuz R, et al. Filgotinib (GLPG0634), an Oral JAK1 selective inhibitor is effective as monotherapy in patients with active rheumatoid arthritis: results from a Phase 2B dose ranging study [abstract]. Arthritis Rheumatol. 2015;67(Suppl10):1049.
   Google Scholar
• Kremer JM, Keystone EC, Emery P, et al. Safety and Efficacy of ABT-494, a novel selective JAK1 inhibitor, in patients with active rheumatoid arthritis and inadequate response or intolerance to anti-TNF biologic therapy [abstract]. Arthritis Rheumatol. 2015;67:Suppl10:14L.
   Google Scholar
• Mahajan S, Hogan JK, Shlyakhter D, et al. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease. J Pharmacol Exp Ther. 2015;353:405–414.
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Damjanov NS, Kivitz AJ, et al. A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. Arthritis Rheumatol. 2015;67:334–343.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Van Vollenhoven RF, Pacheco-Tena C, et al. VX-509 (Decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol. 2016;68:46–55.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1–26.
   PubMed Web of Science ®Google Scholar